Drug Trial Radar · NCT04385277
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Dec 31, 2020
Primary completion
Jun 30, 2023
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy (which usually consists of two autologous stem cell transplants and radiation) who have not experienced worsening or recurrence of their disease. Dinutuximab represents a kind of cancer therapy called immunotherapy. Unlike chemotherapy and radiation, dinutuximab targets the cancer cells without destroying nearby healthy cells. Sargramostim helps the body produce normal infection-fighting white blood cells. Isotretinoin helps the neuroblastoma cells become more mature. These 3 drugs (standard immunotherapy) are already given to patients with high-risk neuroblastoma after Consolidation because they have been proven to be beneficial in this setting. Chemotherapy drugs, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. They may also affect how well immunotherapy works on neuroblastoma cells. Giving chemo-immunotherapy after intensive therapy may work better in treating patients with high-risk neuroblastoma compared to standard immunotherapy.
Conditions
- Ganglioneuroblastoma, Nodular
- Neuroblastoma
Interventions
Biospecimen CollectionProcedure
Correlative studies
Bone Marrow AspirationProcedure
Undergo BM aspiration
Bone Marrow BiopsyProcedure
Undergo BM biopsy
Computed TomographyProcedure
Undergo CT
DinutuximabBiological
Given IV
FDG-Positron Emission TomographyProcedure
Undergo FDG-PET
Iobenguane I-123Radiation
Undergo 123I-MIBG
IrinotecanDrug
Given IV
IsotretinoinDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
SargramostimBiological
Given SC or IV
TemozolomideDrug
Given PO or via enteral tube
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Who Complete 5 Cycles of Dinutuximab + Chemotherapy Without Progressive Disease (PD)Time frame: Within 30 weeks from the date of first treatment
Locations
77 sites in 4 countries. Site status is shown where the registry gives one.
Banner Children's at Desert
Mesa, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
Children's Hospital Los Angeles
Los Angeles, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
University of Florida Health Science Center - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
Nemours Children's Hospital
Orlando, Florida
Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia
Saint Luke's Cancer Institute - Boise
Boise, Idaho
Lurie Children's Hospital-Chicago
Chicago, Illinois
University of Illinois
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Saint Jude Midwest Affiliate
Peoria, Illinois
Riley Hospital for Children
Indianapolis, Indiana
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa
Norton Children's Hospital
Louisville, Kentucky
Ochsner Medical Center Jefferson
New Orleans, Louisiana
Walter Reed National Military Medical Center
Bethesda, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
C S Mott Children's Hospital
Ann Arbor, Michigan
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Children's Mercy Hospitals and Clinics
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
Mercy Hospital Saint Louis
St Louis, Missouri
Children's Hospital and Medical Center of Omaha
Omaha, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Morristown Medical Center
Morristown, New Jersey
Albany Medical Center
Albany, New York
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.